Last reviewed · How we verify
Placebo film
A placebo film formulation serves as an inert control comparator in clinical trials to assess the efficacy of active pharmaceutical agents.
A placebo film formulation serves as an inert control comparator in clinical trials to assess the efficacy of active pharmaceutical agents. Used for Clinical trial control comparator (indication dependent on active drug being studied).
At a glance
| Generic name | Placebo film |
|---|---|
| Also known as | Placebo, Placebo buccal film, BEMA placebo |
| Sponsor | BioXcel Therapeutics Inc |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo films are inactive formulations designed to match the appearance, taste, and administration route of active drug candidates while containing no therapeutic agent. They are used in randomized controlled trials to establish baseline efficacy, safety, and tolerability by comparison against active treatment arms. The placebo effect and natural disease progression can be quantified by measuring outcomes in the placebo-treated group.
Approved indications
- Clinical trial control comparator (indication dependent on active drug being studied)
Common side effects
Key clinical trials
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors (PHASE3)
- A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis (PHASE3)
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP (PHASE2)
- A Research Study of VCT220 in Adult Chinese Participants With Obesity (PHASE3)
- Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (PHASE2)
- Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo film CI brief — competitive landscape report
- Placebo film updates RSS · CI watch RSS
- BioXcel Therapeutics Inc portfolio CI